Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

Código QR

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

Ruiying Kang,1 Yan He,1 Yuxiang Yan,1 Zhiwu Li,2 Yeqing Wu,3 Xiaojuan Guo,4 Zhigang Liang,5 Jun Jiang2 1Department of Epidemiology and Biostatics, School of Public Health, Capital Medical University, Beijing, People’s Republic of China; 2Fengtai Nanyuan Hospital of Beijing, Beijing, Peopl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kang RY, He Y, Yan YX, Li ZW, Wu YQ, Guo XJ, Liang ZG, Jiang J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6754a00c71ac4946a55bc7dfb6f478d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
por: Chen JW, et al.
Publicado: (2018)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima K, et al.
Publicado: (2013)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
por: Kamijima K, et al.
Publicado: (2013)

Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial
por: Che T, et al.
Publicado: (2018)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression
por: Kato M, et al.
Publicado: (2015)

Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial
por: Zuilhof Z, et al.
Publicado: (2018)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak J, et al.
Publicado: (2013)

Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials
por: Yang JR, et al.
Publicado: (2015)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
por: Pecenak J, et al.
Publicado: (2013)

Stanford neuromodulation therapy (SNT): a double-blinded, randomized, and controlled trial
por: Nolan Williams
Publicado: (2021)

A large, prospective, double-blind trial of vagus nerve stimulation in difficult to treat depression
por: CHARLES CONWAY
Publicado: (2021)

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
por: Somaieh Ashrafi, et al.
Publicado: (2022)

Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial
por: Jiaojiao Zhou, et al.
Publicado: (2021)

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
por: Fornaro M, et al.
Publicado: (2013)

Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
por: Yehudit Bloch, et al.
Publicado: (2021)

Probiotics as a treatment for prenatal maternal anxiety and depression: a double-blind randomized pilot trial
por: Pamela D. Browne, et al.
Publicado: (2021)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
por: Han Y, et al.
Publicado: (2016)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki A, et al.
Publicado: (2014)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Robert H Howland
Publicado: (2009)

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
por: Howard E. Gendelman, et al.
Publicado: (2017)

Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
por: Medvedev VE
Publicado: (2017)

Navigated repetitive transcranial magnetic stimulation improves the outcome of postsurgical paresis in glioma patients – A randomized, double-blinded trial
por: Sebastian Ille, et al.
Publicado: (2021)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study
por: Wang G, et al.
Publicado: (2016)

Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial
por: Farnia V, et al.
Publicado: (2015)

A Pilot Double-Blind Placebo-Controlled Randomized Clinical Trial to Investigate the Effects of Early Enteral Nutrients in Sepsis
por: Faraaz Ali Shah, MD, MPH, et al.
Publicado: (2021)

Trazodone effects on [3H]-paroxetine and &alpha;2-adrenoreceptors in platelets of patients with major depression
por: Donatella Marazziti, et al.
Publicado: (2010)

Semi-Individualized Acupuncture for Insomnia Disorder and Oxidative Stress: A Randomized, Double-Blind, Sham-Controlled Trial
por: Yeung WF, et al.
Publicado: (2021)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan MN, et al.
Publicado: (2015)

A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD
por: Cowan J, et al.
Publicado: (2021)

A randomized controlled trial of mindfulness-based Tai Chi Chuan for subthreshold depression adolescents
por: Zhang JY, et al.
Publicado: (2018)

Daily intake of rosehip extract decreases abdominal visceral fat in preobese subjects: a randomized, double-blind, placebo-controlled clinical trial
por: Nagatomo A, et al.
Publicado: (2015)

Light-chain cardiac amyloidosis with neuropathy: a case report
por: Xu ZW, et al.
Publicado: (2015)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report
por: Igata R, et al.
Publicado: (2016)

Vitamin D3 as adjunctive therapy in the treatment of depression in tuberculosis patients: a short-term pilot randomized double-blind controlled study
por: Zhang L, et al.
Publicado: (2018)

A double-blind randomized clinical trial of high frequency rTMS over the DLPFC on nicotine dependence, anxiety and depression
por: Ahmed A. Abdelrahman, et al.
Publicado: (2021)

Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study
por: Hsing SC, et al.
Publicado: (2020)

Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial
por: Jiang Y, et al.
Publicado: (2014)

Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study
por: Usharani P, et al.
Publicado: (2013)